Anti Amyloid Leqembi denied for failing step therapy by UnitedHealthcare?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What UnitedHealthcare typically requires
UnitedHealthcare's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The UnitedHealthcare angle on Anti Amyloid Leqembi
## Why UHC Requires Step Therapy for Leqembi — and Why You Can Appeal
UnitedHealthcare's step-therapy ("fail-first") requirement for Leqembi (lecanemab) demands documented use and failure of specified prior therapies before it will authorize this anti-amyloid agent. For a disease-modifying therapy targeting Alzheimer's amyloid pathology, this structure is clinically problematic: existing symptomatic treatments for Alzheimer's disease act through different mechanisms than lecanemab and do not address the same treatment target. Requiring failure of a symptomatic drug before authorizing a disease-modifying drug conflates two distinct therapeutic categories.
## Why This Denial Is Appealable
Step-therapy requirements are not absolute. Federal law and many state step-therapy exception statutes require the insurer to grant an exception when (a) the required prior drug is clinically contraindicated or inappropriate for the patient, (b) the patient already tried and failed it, or (c) the step-therapy protocol is inconsistent with the applicable clinical practice guideline. Under ACA §2719 and ERISA §503, UHC must provide a full internal appeal and independent external review. You have up to 180 days from the denial to file internally, and the external review window under federal rules is approximately four months from exhaustion of internal remedies. Expedited review is available when delay would cause serious deterioration — a strong argument given the progressive nature of Alzheimer's disease.
## What to Gather
- Mechanism differentiation: The prescriber must document in writing that lecanemab and the required step-therapy drug(s) have distinct mechanisms and non-overlapping therapeutic goals, citing the FDA prescribing information for each.
- Disease-stage urgency: Clinical records establishing that the patient is in an early stage of the disease — the window of eligibility for lecanemab is limited, and delay caused by step-therapy requirements can foreclose access entirely.
- Prior treatment history: Complete dates, outcomes, and reasons for any prior Alzheimer's medications already tried.
- Step-therapy exception grounds: Documentation of any contraindication, intolerance, or clinical inappropriateness of the required prior drugs, if applicable.
- Prescriber medical-necessity letter: A letter from the treating neurologist explaining the mechanistic distinction, the disease-stage urgency, and the applicable neurology guideline organization's recommendation for disease-modifying therapy in confirmed early Alzheimer's disease.
## Criteria-Mapping Approach
Request the exact text of UHC's step-therapy protocol for Leqembi and its published exception criteria. List every requirement. Document whether each prior step was completed (with outcome) or is clinically inappropriate, with the specific clinical reason. If the patient's disease stage means that completing step therapy would cause them to age out of the eligible population or progress to a stage where the drug is no longer indicated, document that progression risk explicitly — it is a medical-necessity argument embedded in the step-therapy appeal.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →